Current Report Filing (8-k)
16 Giugno 2023 - 10:02PM
Edgar (US Regulatory)
0000316253
false
0000316253
2023-06-16
2023-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): June 16, 2023
Enzo
Biochem, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
New
York
(State
or Other Jurisdiction of Incorporation)
001-09974 |
|
13-2866202 |
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
81 Executive Blvd. Suite 3 |
|
|
Farmingdale, New York |
|
11735 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(212) 583-0100
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
Common Stock, $0.01 par value |
|
ENZ |
|
The New York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 - Other
Items
This
Current Report on Form 8-K provides Enzo Biochem, Inc.’s (the “Company”) unaudited pro forma condensed consolidated
financial information as of and for the nine months ended April 30, 2023 and for the years ended July 31, 2022 and July 31, 2021 and
the notes thereto, based upon financial statements prepared in accordance with accounting principles generally accepted in the United
States. Such information is filed as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated into this Item 8.01 by reference.
Forward-Looking
Statements
This
Current Report on Form 8-K contains “forward-looking statements” about the Company’s future expectations, plans, outlook,
projections and prospects. Such forward-looking statements can be identified by the use of words such as “should,” “may,”
“would,” “intends,” “anticipates,” “believes,” “estimates,” “projects,”
“forecasts,” “expects,” “plans,” “proposes” and similar expressions or the negative of
these terms or other comparable terminology, although not all forward-looking statements contain these words. Although the Company believes
that the expectations reflected in these forward-looking statements are based on reasonable assumptions, these statements involve risks,
uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements. Forward-looking statements in this communication include
estimates and assumptions, particularly in regard to unaudited pro forma financial information included in Exhibit 99.1 of this Current
Report on Form 8-K. Accordingly, readers are urged to carefully review and consider any cautionary statements and other disclosures, including
the statements made under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended
July 31, 2022. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In addition, readers
are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking
statements, readers should not rely on these statements in making an investment decision or regard these statements as a representation
or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Forward-looking
statements speak only as of the date of the document in which they are contained, and the Company does not undertake any duty to update
any forward-looking statements except as may be required by law. Therefore, readers should not rely on these forward-looking statements
as representing the Company’s views as of any date subsequent to the date of this communication.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits.
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ENZO BIOCHEM, INC. |
|
|
|
Date: June 16, 2023 |
By: |
/s/ Hamid Erfanian |
|
|
Hamid Erfanian |
|
|
Chief Executive Officer |
2
Grafico Azioni Enzo Biochem (NYSE:ENZ)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Enzo Biochem (NYSE:ENZ)
Storico
Da Nov 2023 a Nov 2024